Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results

Posted by William Tyler on Nov 15th, 2024

Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84, Zacks reports. The firm had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the business earned ($16.50) EPS.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $12.77 on Friday. Atara Biotherapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The company has a 50 day moving average price of $8.95 and a 200 day moving average price of $10.32.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ATRA. Canaccord Genuity Group increased their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Finally, Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their target price for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Atara Biotherapeutics has a consensus rating of “Hold” and a consensus price target of $16.67.

Check Out Our Latest Stock Report on Atara Biotherapeutics

About Atara Biotherapeutics

(Get Free Report)

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.